The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Department of Internal Medicine "H", Rambam Health Care Campus, Haifa, Israel; Management, Rambam Health Care Campus, Haifa, Israel.
The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Management, Rambam Health Care Campus, Haifa, Israel; Department of Haematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
Clin Microbiol Infect. 2022 Dec;28(12):1644-1648. doi: 10.1016/j.cmi.2022.07.002. Epub 2022 Jul 15.
This study sought to correlate the SARS-CoV-2 IgG antibody response level to the BNT162b2 (Pfizer BioNTech) mRNA vaccine after the first and second doses with the reported adverse events.
This cohort study examined the adverse events profiles of people vaccinated with BNT162b2 in our institute between late 2020 and May 2021. Adverse events, age, and sex were reported using an electronic questionnaire, and their SARS-CoV-2 IgG antibody levels were retrieved from the hospital database.
Between 20 December 2020 and 31 May 2021, the adverse events questionnaire was completed by 9700 individuals who received the first vaccine dose and 8321 who received the second dose. After the first and second doses, the average antibody levels were 62.34 AU/mL (mean 4-373) and 188.19 AU/mL (mean 20-392), respectively. All of the adverse events, except local pain, were more common after the second vaccine dose. Multivariate analysis showed that after the first vaccine dose, female sex and younger age (but not IgG titres) were associated with a higher probability of adverse events (OR 2.377, 95% CI, 1.607-3.515, p = 0.000; OR 0.959, 95% CI, 0.944-0.977, p £0.000; OR 1.002, 95% CI, 0.995-1.008, p £0.601; respectively); however, all three parameters were associated with the incidence of adverse events after the second dose (OR 2.332, 95% CI, 1.636-3.322, p = 0.000; OR 0.984, 95% CI, 0.970-0.999, p £0.039; OR 1.004, 95% CI, 1.001-1.007, p £0.022; respectively).
Adverse events are significantly more common after the second BNT162b2 vaccine dose than after the first dose. We found an association between sex, age, and SARS-CoV-2 IgG antibody titre with the incidence of adverse events.
本研究旨在探讨首次和第二次接种 BNT162b2（辉瑞-生物技术）mRNA 疫苗后，SARS-CoV-2 IgG 抗体反应水平与报告的不良事件之间的相关性。
本队列研究检查了我院于 2020 年末至 2021 年 5 月期间接种 BNT162b2 的人群的不良事件概况。使用电子问卷报告不良事件、年龄和性别，并从医院数据库中检索 SARS-CoV-2 IgG 抗体水平。
2020 年 12 月 20 日至 2021 年 5 月 31 日期间，9700 名接受第一剂疫苗和 8321 名接受第二剂疫苗的个体完成了不良事件问卷。在首次和第二次接种后，平均抗体水平分别为 62.34 AU/mL（均值 4-373）和 188.19 AU/mL（均值 20-392）。除局部疼痛外，所有不良事件在第二次疫苗接种后更为常见。多变量分析显示，在首次接种疫苗后，女性和年龄较小（但 IgG 滴度除外）与发生不良事件的概率更高相关（OR 2.377，95%CI，1.607-3.515，p=0.000；OR 0.959，95%CI，0.944-0.977，p £0.000；OR 1.002，95%CI，0.995-1.008，p £0.601）；然而，所有三个参数均与第二次接种后不良事件的发生相关（OR 2.332，95%CI，1.636-3.322，p=0.000；OR 0.984，95%CI，0.970-0.999，p £0.039；OR 1.004，95%CI，1.001-1.007，p £0.022）。
BNT162b2 第二次疫苗接种后不良事件明显比第一次更常见。我们发现性别、年龄和 SARS-CoV-2 IgG 抗体滴度与不良事件的发生之间存在关联。
